Castle Biosciences CSTL Business Segments — Total stock-based compensation expense

Similar metrics at other companies

ZMReportable Segment — Total stock-based compensation expense

$178.95M-11.2%

STEMReportable Segment — Total stock-based compensation expense

$2.05M-52.6%

SCORReportable Segment — Total stock-based compensation expense

$825K+11.8%

BKSYReportable Segment — Total stock-based compensation expense

$3.93M+42.4%

DASHReportable Segment — Total stock-based compensation expense

$349M+23.8%

PRAXReportable Segment — Total stock-based compensation expense

$11.31M+45.5%

FAQ

What is Castle Biosciences's business segments — total stock-based compensation expense?

Castle Biosciences (CSTL) reported business segments — total stock-based compensation expense of $9.78M in Q1 2026.

How has Castle Biosciences's business segments — total stock-based compensation expense changed year-over-year?

Castle Biosciences's business segments — total stock-based compensation expense decreased by 12.6% year-over-year, from $11.18M to $9.78M.

What is the long-term trend for Castle Biosciences's business segments — total stock-based compensation expense?

Over 3 years (2022 to 2025), Castle Biosciences's business segments — total stock-based compensation expense has grown at a 8.1% compound annual growth rate (CAGR), from $36.32M to $45.89M.

What does business segments — total stock-based compensation expense mean?

This represents the total non-cash expense recognized for equity-based awards granted to employees and personnel within the reportable segment. It serves as a measure of the cost of human capital retention and alignment through equity incentives.